Efficacy of duloxetine and selective serotonin reuptake inhibitors: Comparisons as assessed by remission rates in patients with major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 27, Issue 6, 2007, Pages 672-676

  Thase, Michael E ^a,b,c   Pritchett, Yili Lu ^d   Ossanna, Melissa J ^e   Swindle, Ralph W ^e   Xu, Jimmy ^e   Detke, Michael J ^e,f,g,h  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d ABBOTT LABORATORIES   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MCLEAN HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HUMANS; PAROXETINE; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; TREATMENT OUTCOME;

EID: 39649113145     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31815a4412     Document Type: Article

References (23)

1. Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J Clin Psychiatry. 1999;60:7-11.
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. 2nd ed. Washington, DC: American Psychiatric Association; 2000.
3. Nelson JC. Synergistic benefits of serotonin and noradrenaline reuptake inhibition. Depress Anxiety. 1998;7:5-6.
4. Shelton C, Entsuah AR, Padmanabhan SK, et al. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol. 2005;20:233-238.
5. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396-404.
6. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
7. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull. 2002;(36 suppl 1):S1-S17.
8. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
9. Perahia DG, Wang F, Mallickrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry. 2006;21:367-378.
10. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308-315.
11. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res. 2002;36:383-390.
12. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389-399.
13. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull. 2002; 36:106-132.
14. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457-470.
15. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Onset of antidepressant action and acute efficacy and safety of duloxetine versus escitalopram and placebo in the treatment of major depressive disorder. Neuropsychopharmacology. 2005;30:S142.
16. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
17. Landin R, DeBrota DJ, DeVries TA, et al. The impact of restrictive entry criterion during the placebo lead-in period. Biometrics. 2000; 56:271-278.
18. Gleser LJ, Olkin I. Meta-analysis for 2X2 tables with multiple treatment groups. In: Stangl DK, Berry DA, eds. Meta-analysis in Medicine and Health Policy. New York, NY: Marcel Dekker, Inc; 2000:179-189.
19. Thase ME, Ahmed S, Entsuah R, et al. Meta-analysis and funnel plot analysis of studies comparing venlafaxine and selective serotonin reuptake inhibitors: the evidence revisited. Neuropsychopharmacology. 2004;29:S238.
20. Khan A, Khan SR, Walens G, et al. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the Food and Drug Administration summary basis of approval reports. Neuropsychopharmacology. 2003;28:552-557.
21. Thase ME. How should efficacy be evaluated in randomized clinical trials of treatments for depression? J Clin Psychiatry. 1999;(60 suppl 4): 23-31.
22. Khan A, Leventhal RM, Khan SR, et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22:40-45.
23. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs. 1999;57:507-533.